A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Clinical Trial

Official title:

An Open-Label Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01240694
• Other study ID #: C33457/3075
• Status: Terminated
• Phase: Phase 3
• Start date: December 9, 2010
• Est. completion date: June 14, 2012

Study information

• Verified date: November 2022
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (SC) CEP-33457 for injection every 4 weeks over 72 weeks (18 doses) in participants with systemic lupus erythematosus (SLE) who have participated in a previous Cephalon sponsored clinical study of CEP-33457, and completed at least Visit 8 (Week 24 of that study).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 136
• Est. completion date: June 14, 2012
• Est. primary completion date: June 14, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• The participant has an established diagnosis of SLE as defined by ACR Classification Revised Criteria. The diagnosis is fulfilled provided that at least 4 criteria are met.

• The participant previously participated in and completed at least Visit 8 (Week 24) the Cephalon sponsored clinical study with CEP-33457 (study C33457/2047) and, in the investigator's opinion, would benefit from continued participation in a clinical study.

• Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, using a medically accepted method of contraception, and must agree to continued use of this method for the duration of the study and for 30 days after discontinuation of study drug treatment.

Exclusion Criteria:

• The participant has New York Heart Association (NYHA) Class III or IV congestive heart failure.

• The participant has an estimated glomerular filtration rate (eGFR) of less than 30 milliliters (mL)/minute (min)/1.73 square meter (m^2) (via Modification of Diet in Renal Disease [MDRD] equation).

• The participant has an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value greater than 2 times the upper limit of normal (ULN) or a total bilirubin level greater than 1.5 times ULN.

• The participant has a planned immunization with a live or live attenuated vaccine within 3 months prior to administration of the first dose of study drug and for 3 months after administration of the last dose of study drug.

• The participant has any clinically significant abnormalities on electrocardiogram (ECG) that are not related to SLE, as determined by the investigator. Participants with stable ECG changes without evidence of active cardiovascular disease may participate at the discretion of the investigator and medical monitor.

• The participant has an ongoing active systemic infection requiring treatment or a history of severe infection, such as hepatitis or pneumonia, in the 3 months prior to administration of the first dose of study drug. Less severe infections in the 3 months prior to administration of the first dose of study drug are permitted at the discretion of the investigator and medical monitor.

• The participant has any concomitant medical condition unrelated to SLE that may interfere with his or her safety or with evaluation of the study drug, as determined by the investigator.

• The participant has a history of a positive test result for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab).

• The participant has a known positive history of antibodies to human immunodeficiency virus (HIV) or HIV disease.

• The participant has a history of alcohol or substance dependence or abuse (with the exception of nicotine), according to the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, Fourth Edition, Text Revision (DSM-IV-TR), within 3 months of the screening visit for study C33457/2047, or has current substance abuse.

• The participant has a history of severe allergic reactions to or hypersensitivity to any component of the study drug.

• The participant is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)

• The participant has undergone or is undergoing treatment with another investigational drug for the treatment of lupus within 6 months prior to the 1st dose of study drug or has received any other investigational drug for any other condition within 30 days prior to the 1st dose of study drug, except for treatment with CEP-33457 or placebo in study C33457/2047.

• The participant has a known history of antibodies to CEP-33457.

• The participant is unlikely to comply with the study protocol or is unsuitable for any other reason, as judged by the investigator or medical monitor.

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Intervention

Drug:
• CEP-33457
CEP-33457 will be administered subcutaneously per dose specified in the arm description.

Locations

Country	Name	City	State
Belgium	Teva Investigational Site 102	Brussel
Belgium	Teva Investigational Site 101	Liege
Belgium	Teva Investigational Site 100	Yvoir
Czechia	Teva Investigational Site 201	Brno
Czechia	Teva Investigational Site 200	Olomouc
Czechia	Teva Investigational Site 202	Prague 2
Czechia	Teva Investigational Site 203	Prague 2
France	Teva Investigational Site 301	Lille
France	Teva Investigational Site 302	Nantes
France	Teva Investigational Site 300	Paris
France	Teva Investigational Site 303	Paris
France	Teva Investigational Site 304	Strasbourg
Germany	Teva Investigational Site 402	Aachen
Germany	Teva Investigational Site 403	Berlin
Germany	Teva Investigational Site 401	Dresden
Germany	Teva Investigational Site 404	Dusseldorf
Germany	Teva Investigational Site 406	Hamburg
Germany	Teva Investigational Site 405	Mainz
Germany	Teva Investigational Site 400	Munchen
Hungary	Teva Investigational Site 501	Budapest
Hungary	Teva Investigational Site 502	Debrecen
Hungary	Teva Investigational Site 500	Zalaegerszeg
Poland	Teva Investigational Site 603	Dabrowka
Poland	Teva Investigational Site 600	Elblag
Poland	Teva Investigational Site 602	Konskie
Poland	Teva Investigational Site 601	Lublin
Poland	Teva Investigational Site 604	Lublin
Poland	Teva Investigational Site 606	Warszawa
Poland	Teva Investigational Site 605	Wroclaw
Portugal	Teva Investigational Site 701	Amadora
Portugal	Teva Investigational Site 702	Coimbra
Portugal	Teva Investigational Site 700	Porto
Portugal	Teva Investigational Site 703	Porto
Spain	Teva Investigational Site 751	Dresden
Spain	Teva Investigational Site 752	Santander
Spain	Teva Investigational Site 750	Sevilla
Ukraine	Teva Investigational Site 901	Donetsk
Ukraine	Teva Investigational Site 905	Ivano-Frankivsk
Ukraine	Teva Investigational Site 900	Kyiv
Ukraine	Teva Investigational Site 902	Kyiv
Ukraine	Teva Investigational Site 903	Kyiv
Ukraine	Teva Investigational Site 904	Lviv
United Kingdom	Teva Investigational Site 803	Bath
United Kingdom	Teva Investigational Site 801	Leeds
United Kingdom	Teva Investigational Site 800	London
United Kingdom	Teva Investigational Site 802	Newcastle Upon Tyne
United States	Teva Investigational Site 22	Ann Arbor	Michigan
United States	Teva Investigational Site 19	Arlington	Virginia
United States	Teva Investigational Site 31	Atlanta	Georgia
United States	Teva Investigational Site 8	Atlanta	Georgia
United States	Teva Investigational Site 30	Aurora	Colorado
United States	Teva Investigational Site 4	Aventura	Florida
United States	Teva Investigational Site 36	Baltimore	Maryland
United States	Teva Investigational Site 27	Birmingham	Alabama
United States	Teva Investigational Site 10	Boston	Massachusetts
United States	Teva Investigational Site 3	Chapel Hill	North Carolina
United States	Teva Investigational Site 15	Charleston	South Carolina
United States	Teva Investigational Site 28	Charlotte	North Carolina
United States	Teva Investigational Site 32	Clearwater	Florida
United States	Teva Investigational Site 23	Coeur d'Alene	Idaho
United States	Teva Investigational Site 29	Dallas	Texas
United States	Teva Investigational Site 25	Duncansville	Pennsylvania
United States	Teva Investigational Site 18	Durham	North Carolina
United States	Teva Investigational Site 35	Fort Lauderdale	Florida
United States	Teva Investigational Site 40	Houston	Texas
United States	Teva Investigational Site 6	Houston	Texas
United States	Teva Investigational Site 1	Jupiter	Florida
United States	Teva Investigational Site 37	Lexington	Kentucky
United States	Teva Investigational Site 16	Los Angeles	California
United States	Teva Investigational Site 5	Los Angeles	California
United States	Teva Investigational Site 9	Manhasset	New York
United States	Teva Investigational Site 39	Mesquite	Texas
United States	Teva Investigational Site 33	Milwaukee	Wisconsin
United States	Teva Investigational Site 2	Monroe	North Carolina
United States	Teva Investigational Site 21	Oklahoma City	Oklahoma
United States	Teva Investigational Site 26	Pittsburgh	Pennsylvania
United States	Teva Investigational Site 34	San Antonio	Texas
United States	Teva Investigational Site 7	San Diego	California
United States	Teva Investigational Site 14	San Leandro	California
United States	Teva Investigational Site 12	Seattle	Washington
United States	Teva Investigational Site 17	Stanford	California
United States	Teva Investigational Site 38	Stockbridge	Georgia
United States	Teva Investigational Site 11	Tampa	Florida
United States	Teva Investigational Site 24	Temple	Texas
United States	Teva Investigational Site 20	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Cephalon, Inc.

Countries where clinical trial is conducted

United States,  Belgium,  Czechia,  France,  Germany,  Hungary,  Poland,  Portugal,  Spain,  Ukraine,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events (AEs)	An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included clinically significant vitals, labs, and physical examination findings. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.	Baseline up to Week 72
Primary	Number of Participants Who Received Concomitant Medications	Any concomitant therapy or medication taken while the participant received study drug.	Baseline up to Week 72
Secondary	Number of Participants Achieving a Clinical Response Using the Systemic Lupus Erythematosus (SLE) Responder Index (SRI)	An SRI response was defined as a reduction from baseline in SLE Disease Activity Index 2000 (SLEDAI-2K) score of =4 points, no worsening in Physician Global Assessment (PhGA), no new British Isles Lupus Assessment Group (BILAG) A body system score, and =1 new BILAG B body system score from baseline. SLEDAI 2K includes 24 weighted clinical and laboratory variables. Total score = 0 to 105. A score of 6 to 10 = moderate disease activity, and a reduction of >3 points = improvement. PhGA was completed by physician using a visual analog scale (VAS) from 0=none to 3=severe. A change of >0.3 points = worsening. BILAG includes 97 clinical and laboratory items. Each organ system is assigned a score displayed as a grade from A to E: A=very active disease; B=participant needs increase in treatment for moderately active disease; C=stable or mild disease; D=previous organ involvement but no current disease activity; and E=no current disease activity and organ system has never been involved.	Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72
Secondary	Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Total Score	The SLEDAI-2K is a validated objective measure that assesses disease activity within the last 28 days before completion of the index. It is a global index and includes 24 weighted clinical and laboratory variables. The total score (sum of all 24 scores) ranges from 0 to 105, with higher scores representing increased disease activity.	Baseline, Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64 and Final Assessment (or Early Termination [up to Week 72])
Secondary	Number of Participants With British Isles Lupus Assessment Group 2004 (BILAG-2004) Response	The BILAG-2004 is a validated objective and subjective global measure of the SLE disease activity, based on the physician's intention to treat, and refers to disease activity within the last 4 weeks before completion of the index. It includes 97 clinical and laboratory components to evaluate SLE disease activity in 9 different body systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematological). Each body system is assigned a score displayed as a grade from A to E, as follows: A=very active disease; B=participant needs increase in treatment for moderately active disease; C=stab1e or mild disease; D=previous system involvement but no current disease activity; and E=no current disease activity and the body system has never been involved. BILAG 2004 response was defined as no new BILAG A body system score and no more than 1 new BILAG B body system score from baseline.	Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72
Secondary	Number of Participants Showing No Worsening on Physician's Global Assessment (PhGA) Scale	The PhGA was completed by the physician using a 3-inch visual analog scale (VAS) labeled from 0=none to 3=severe. A change of greater than 0.3 point on the VAS indicates worsening. The number of participants showing no worsening are presented.	Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68 and 72
Secondary	Number of Participants Showing No Worsening on Patient's Global Assessment (PtGA) Scale	The PtGA was completed by the participant, using a 3-inch VAS labeled from 0=none to 3=severe. A change of greater than 0.3 point on the VAS indicated worsening. The number of participants showing no worsening are presented.	Week 12, 24, 36, 48, 60, and 72
Secondary	Change From Baseline in Short-Form 36 (SF-36) Domain Scores	The SF-36 questionnaire has 36 questions composing the scale that represent 8 domains: 1) physical functioning, 2) physical role functioning, 3) bodily pain, 4) general health, 5) vitality, 6) social functioning, 7) emotional role functioning, and 8) mental health. All domains are scored on a scale from 0 (worst) to 100 (best), with higher scores representing the best possible health state. Change from baseline scores in the following individual standardized domains: Bodily pain, physical functioning, social functioning and vitality were presented.	Baseline, Week 12, 24, 36, 48, 60 and final assessment (or early termination [up to Week 72])
Secondary	Change From Baseline in the Biomarker: Anti-U1 Ribonucleoprotein Antibody (Anti-UI RNP Ab)	Anti-UI RNP Ab was measured from blood serum collected at specified time points.	Baseline, Week 12, 24, 36, 48, 60 and final assessment (or early termination [up to Week 72])
Secondary	Change From Baseline in the Biomarker: C-Reactive Protein (CRP)	CRP was measured from blood serum samples at specified time points.	Baseline, Week 12, 24, 36, 48, 60, and Final Assessment (or Early Termination [up to Week 72])
Secondary	Number of Participants With Anti-nuclear Antibodies (ANA)	Anti-nuclear antibodies (ANA) were measured from blood serum samples at specified time points.	Week 12, 24, 36, 48, 60, and Final Assessment (or Early Termination [up to Week 72])
Secondary	Number of Participants With Mild to Moderate Flare, Severe Flare, and No Flare, Based on the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) Flare Index	The SELENA Flare Index divides flares into 2 categories: mild/moderate and severe. A severe flare would lead to early withdrawal. The number of participants with mild to moderate flare, severe flare, and no flare at each visit during the treatment period were reported.	Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64 and Final Assessment (or Early Termination [up to Week 72])
Secondary	Change From Baseline in Total Damage Score as Assessed by the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index	The SLICC/ACR damage index assesses specific comorbidities associated with SLE. It consists of 41 items and covers 12 body systems. Total damage scores were calculated using the 41 items. The total damage score ranges from 0 (no damage) to 47 (maximum disease damage severity) with higher scores indicating increasing disease damage severity.	Baseline, Week 24, 48 and Final Assessment (or Early Termination [up to Week 72])
Secondary	Number of Participants Achieving Remission of Disease	Remission of disease was defined as a reduction of SLEDAI-2K score to 0. The SLEDAI-2K is a validated objective measure that assesses disease activity within the last 28 days before completion of the index. It is a global index and includes 24 weighted clinical and laboratory variables. The total score (sum of all 24 scores) ranges from 0 to 105, with higher scores representing increased disease activity.	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64 and Final Assessment (or Early Termination [up to Week 72])
Secondary	Number of Participants With Change in Steroid Dose	Number of participants with change in steroid dose (prednisone equivalent/day) were reported. The change in steroid dose was evaluated to determine the number of participants taking a dose less than 7.5 mg of prednisone equivalent/day, a dose of 7.5 mg prednisone equivalent/day or more, and none per day.	From Baseline up to Final Assessment (or Early Termination [up to Week 72])
Secondary	Number of Participants With Reactive and Non-Reactive Anti-CEP-33457 Antibodies	Immunogenicity was assessed by detection of the presence of specific anti-CEP-33457 antibodies in blood serum samples collected at the specified time points.	Week 24, 48 and Final Assessment (or Early Termination [up to Week 72])